Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$11.27 USD
-0.45 (-3.84%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 1 - 20 ( 146 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: Back at Helm With CD388; Phase 2b NAVIGATE Begins 3Q24; Upgrade to Buy With $24 PT on Renewed Outlook
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In Transformational Moves, Cidara Reacquires Rights to CD388 From Janssen and Divests Rezafungin; Rating Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AACR Presentations Highlight Cidara''s Growing Oncology DFC Franchise
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
REZZAYO Enters Into a Key Market in Europe; Next Milestone is ReSTORE Data Readout in China in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
REZZAYO Now Approved in Europe; Phase 3 Top-line Readout in 2Q24 Could Support Approval in China
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 ReSTORE Trial Completed Enrollment in China; Topline Data Expected in 2Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; REZZAYO''s EC Approval Expected By Year-End 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IDWeek 2023 Presentations Highlight CD388''s Protection Against Influenza Regardless of Immune Status; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Anticipate REZZAYO''s European Approval For Invasive Candidiasis Based on CHMP''s Positive Opinion; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RD Day Highlights DFC''s Potential in Oncology; First-in - Human Study Expected to Begin in Mid-2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Janssen?s CD388 Collaboration Opt-in Is a Net Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; REZZAYO Now Available in the U.S.; Cidara to Provide Updates on Cloudbreak Programs in RD Day; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
REZZAYO Commercial Launch Announced By U.S. Partner Melinta; RD Day to Update Cloudbreak Programs; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CD388 Collaborative Agreement With Janssen Could Be Impacted By Business Prioritization Plan; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CD421 Shows Potential Against Other Oncology Treatment Modalities; CD388 Receives Fast Track Designation; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap; Working Towards New Milestones After REZZAYO''s Approval; IND Filing of First Oncology DFC in 2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: Financing and Labeling Concerns Overshadow REZZAYO Approval; Focus to Shift to CD388 for Influenza
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves REZZAYO for the Treatment of Candidemia and Invasive Candidiasis in Adults: Lower PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CBO-212 Shows Potential Versus Other Oncology Therapeutic Modalities in Presentation at ESMO-TAT; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Data on CD388 From Influenza Challenge Study; Rezafungin Approaching March 22 PDUFA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E